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Commentary
Comment on: Evans RJ, Pline K, Loynes CA, Needs S, 
Aldrovandi M, Tiefenbach J, Bielska E, Rubino RE, Nicol 
CJ, May RC, Krause HM, O’Donnell VB, Renshaw SA, 
Johnston SA. 15-keto-prostaglandin E2 activates host per-
oxisome proliferator-activated receptor gamma (PPAR-γ) to 
promote Cryptococcus neoformans growth during infection. 
PLoS Pathog. 2019 Mar;15(3):e1007597. doi: 10.1371/jour-
nal.ppat.1007597. eCollection 2019 Mar. PubMed PMID: 
30921435; PubMed Central PMCID: PMC6438442.
Cryptococcus neoformans is a pathogenic fungus that is 
ubiquitous in our everyday environment, but only those with 
severe or unusual immune deficiencies, such as HIV AIDS, 
develop serious disease.1 During infection Cryptococcus 
forms a close interaction with host macrophages—after 
phagocytosis by macrophages Cryptococcus is able survive 
and replicate within the phagosome, subverting macrophage 
function and turning the macrophage into a niche for the 
establishment of infection.2 To kill Cryptococcus, macro-
phages must be activated by a Th1 CD4+ T-cell-mediated 
adaptive immune response (hence the prevalence in HIV 
AIDS patients)3; failure to control intracellular infection can 
lead to dissemination from the lungs into the central nervous 
system and the development of fatal fungal meningitis.
Cryptococcus can influence the activation state of infected 
macrophages, shifting them from protective Th1 activation 
states to a nonprotective Th2 state although the biological 
mechanisms behind this are unclear.4 Our hypothesis for this 
study was that this manipulation might be mediated by eico-
sanoid species produced by the fungus.5 Cryptococcus can 
produce a number of eicosanoid species which closely resem-
ble those found in the host but natural purpose of these lipids 
normally associated with cell to cell signaling in multicellular 
organisms is unknown.6 Macrophages and other innate 
immune cells are highly responsive to eicosanoid species such 
as prostaglandins and leukotrienes so we reasoned that eico-
sanoids produced by the fungus during intracellular infection 
could interfere with normal host signaling pathways.
Quantifying Eicosanoids During 
Cryptococcus Infection and Determining 
Their Source
Very little is known about eicosanoid synthesis pathways 
in Cryptococcus; only two Cryptococcus enzymes—
phospholipase B1 (PLB1) and laccase (LAC1)—have been 
linked to eicosanoid synthesis in the fungus.7,8 The lack of 
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Abstract
In our recent publication, we show for the first time that the fungal pathogen Cryptococcus neoformans is able to manipulate 
host cells by producing eicosanoids that mimic those found in the host. Using complementary in vivo zebrafish and in vitro 
macrophage cell culture models of Cryptococcus infection, we found that these eicosanoids manipulate host innate immune 
cells by activating the host receptor PPAR-gamma which is an important regulator of macrophage inflammatory phenotypes. 
We initially identified PGE2 as the eicosanoid species responsible for this effect; however, we later found that a derivative 
of PGE2—15-keto-PGE
2
—was ultimately responsible and that this eicosanoid acted as a partial agonist to PPAR-gamma. 
In this commentary, we will discuss some of the concepts and conclusions in our original publication and expand on their 
implications and future directions.
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homologs to eicosanoid synthesis enzymes found in higher 
organisms suggests that the pathway is distinct from any-
thing previously described. Deletion mutants for PLB18 and 
LAC19 have been characterized in Cryptococcus. The PLB1 
mutant ('plb1) shows a profound decrease in all eicosanoids 
produced by C neoformans suggesting this enzyme is central 
to eicosanoid synthesis—possibly fulfilling a role analogous 
to phospholipase A
2
 in mammalian cells. The LAC1 mutant 
('lac1) is deficient in only PGE
2
 and its derivative 15-keto-
PGE
2
, suggesting this enzyme might fulfill a role analogous 
to prostaglandin E
2
 synthase in mammalian cells. Both of 
these strains were used in our study to differentiate between 
host- and pathogen-derived eicosanoids; to aid the study of 
these strains in our zebrafish model, we produced green 
fluorescent protein–tagged versions of each strain. 'plb1 is 
known to have a growth defect in macrophages,10 whereas 
laccase activity has been found to positively correlate 
with increased mortality in patients with HIV-associated 
cryptococcosis11—although how much this is due to PGE
2
 
synthesis as opposed to the role of laccase in the production 
of another cryptococcal virulence factor melanin. In our 
study, we were able to rescue the in vitro intracellular pro-
liferation defect of 'plb1 with exogenous PGE
2
; we also 
found that both 'plb1 and 'lac1 had reduced in vivo growth 
in our zebrafish larvae cryptococcosis model; however, 
only 'plb1-infected fish responded to exogenous PGE
2
 or 
15-keto-PGE
2
.5 We attribute 'lac1’s unresponsiveness to 
exogenous prostaglandin treatment to the fact that laccase is 
also responsible for aforementioned melanin synthesis—
thus, it is possible that for this strain both melanin and PGE
2
 
are required for wild-type levels of growth—or an unknown 
defect that was responsible for it being much more attenu-
ated in animal infection than the 'plb mutant. We attempted 
to circumvent this difference by disrupting the macrophage 
immune response but found that any immunocompromise of 
this response was critical to survival and confounded any 
differences.12
A major challenge we faced in our study was measuring 
eicosanoid levels during host-pathogen interactions and 
determining whether the eicosanoids measured were host or 
pathogen derived. A previous study by Shen and Liu13 found 
that pulmonary levels of PGE2 increased in mice infected 
with C neoformans; however, they were unable to attribute 
this to host or pathogen production. In our study, we per-
formed experiments to measure differences in PGE
2
 content 
between wild-type H99 and 'plb1-infected macrophages 
using 2 different methods—ELISA (enzyme-linked immu-
nosorbent assay) and LC MS/MS (liquid chromatography-
tandem mass spectrometry). We found that J774 macrophages 
did produce detectable levels of PGE
2
; however, we did not 
see any significant difference between infected or uninfected 
macrophages or between H99, 'plb1 and 'plb1:PLB1-
infected cells (although the concentrations detected with 
ELISA and LC MS/MS were very similar).5 This suggested 
that Cryptococcus-derived eicosanoids present during infec-
tion were likely to be contained within the macrophage. 
Measurement of these small, localized eicosanoid levels 
within infected macrophages proved very difficult with cur-
rent analytical methods—to our knowledge, intracellular 
levels of pathogen-derived eicosanoids have never been 
quantitatively measured before. To overcome this difficulty, 
we took a different approach; we used a co-infection assay 
which has previously been used to investigate the interac-
tion of different Cryptococcus gattii strains within the same 
macrophage.14 We predicted that the parental cryptococcal 
strain produced growth-promoting eicosanoids but 'plb1 
could not; the 'plb1 strain should display improved intracel-
lular replication when H99 is also present within the same 
macrophage. Indeed, we found that 'plb1 proliferated better 
when accompanied by 2 wild-type yeast cells in the same mac-
rophage as opposed to when 2 'plb1 yeast cells were accom-
panied by 1 wild-type yeast cell. These experiments confirmed 
to us that Cryptococcus produced eicosanoids during macro-
phage infection and suggested that they did remain contained 
within the macrophage—important because it indicated that 
any host receptor targeted was likely to be intracellular.
Identifying a Mechanism
Our initial experiments indicated that PGE
2
 was the eico-
sanoid species required for Cryptococcus growth because 
exogenous addition of this species was sufficient to rescue 
the growth defects of 'plb1 in J774 macrophages and zebraf-
ish larvae. Intending to boost the observed effects of PGE
2
, 
we used a chemically altered version of PGE
2
 called 16,16 
dimethyl PGE
2
 that cannot be metabolized.15 To our surprise, 
the opposite outcome occurred—16,16-dimethyl PGE
2
 could 
no longer rescue the growth of 'plb1. Under physiological 
conditions, PGE
2
 can be further converted to 15-keto-PGE
2
 
by the enzyme 15-hydroxy prostaglandin dehydrogenase 
(PGDH; Figure 1).16 We assumed that conversion from PGE
2
 
to 15-keto-PGE
2
 could be a way for the host to mitigate the 
effects of Cryptococcus-derived (or exogenously added) 
PGE
2
. This was a eureka moment for our study because we 
realized that conversion of PGE
2
 into 15-keto-PGE
2
 was 
actually required for the growth of Cryptococcus and that if 
host eicosanoid signaling was being affected it was through 
a 15-keto-PGE
2
 receptor rather than a PGE
2
 receptor.
Our experiments had shown that Cryptococcus-derived 
15-keto-PGE
2
 promoted cryptococcal growth and that any host 
receptors involved were likely to be intracellular (Figure 1). 
While searching for putative receptors, we found that 15-keto-
PGE
2
 had been reported to be an agonist for peroxisome prolif-
erator–activated receptor gamma (PPARJ)—an intracellular 
receptor that is known to control inflammatory responses. 
PPARJ is a cytosolic receptor that has a variety of ligands 
including many lipid eicosanoids. Ligand binding leads to the 
formation of a heterodimer between PPARJ and retinoid X 
receptor (RXR). Following heterodimer formation, the PPARJ/
RXR complex translocates to the nucleus and acts as a tran-
scription factor controlling the expression of genes which pos-
sess a peroxisome proliferator hormone response element.17
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Through in vivo experiments with a transgenic zebrafish 
PPARJ reporter, we found that 15-keto-PGE
2
 was unable 
to activate the PPARJ reporter itself; however, when 15-keto-
PGE
2
 was added in combination with a full PPARJ agonist 
troglitazone, the level of PPARJ activation was reduced 
compared with a troglitazone-only control. This indicated 
that 15-keto-PGE
2
 could interact with PPARJ in some capac-
ity either as a partial agonist (a partial agonist is an agonist 
that binds to a receptor with a weak affinity and as a result 
does not fully activate the receptor) or an antagonist. To 
resolve this question, we proved that the effects of 15-keto-
PGE
2
 were reversed by a known PPARJ antagonist. From 
these data, we concluded that 15-keto-PGE
2
 is a partial ago-
nist to PPARJ, a finding that is supported by a previous 
study18 (Figure 1). Interestingly, we settled on this conclu-
sion through interpretation of our data and it was only after-
ward that we became aware of other partial agonists against 
PPARJ.19,20 The protein structure of PPARJ has evolved to 
provide different binding sites for full and partial agonists 
within the PPARJ ligand-binding domain (LBD)—full ago-
nists bind to and stabilize the H12 alpha-helix of the LBD 
which produces a binding site for PPARJ transactivators. 
In contrast, partial agonists do not interact with the H12 
alpha-helix and as a result do not provide stabilization of 
this region but binding still produces PPARJ activation to 
varying magnitudes.21 Partial agonism is a mechanism that 
allows great flexibility in transcription factor function, rather 
than modulating the full gamut of PPARJ-controlled genes, a 
partial agonist will only activate a subset of these genes. This 
means a receptor like PPARJ can produce a variety of differ-
ent transcriptional responses depending on the partial ago-
nists present.
Future Perspectives
1. Where is PGE
2
 metabolized into 15-keto-PGE
2
 dur-
ing infection? PGE
2
 is quickly metabolized into 
15-keto-PGE
2
 in living cells (Figure 1). In higher 
organisms, this reaction is performed by PGDH. It 
is therefore possible that PGE
2
 produced by 
Cryptococcus is metabolized into 15-keto-PGE
2
 by 
the host. 15-keto-PGE
2
 has been detected in the 
supernatant of Cryptococcus cultures so it is also 
likely that Cryptococcus possesses an enzyme similar 
in function to PGDH.
2. What is the effect of PPARJ activation by 15-keto-
PGE
2
 on host cells—specifically host macrophages? 
We have found that 15-keto-PGE
2
 is a partial agonist 
to PPARJ; this means that agonist binding only modu-
lates a subset of PPARJ-controlled genes (Figure 1). 
Identifying this subset in host cells will be essential to 
understand how 15-keto-PGE
2
 enables Cryptococcus 
to cause infection.
3. Do other Cryptococcus-derived eicosanoids promote 
virulence? Our study has focused on PGE
2
/15-keto-
PGE
2
 production by Cryptococcus. We also tested 
PGD
2
 but found this had no effect on infection. 
Cryptococcus produces many more eicosanoids 
which could have synergistic effects to PGE
2
/15-
keto-PGE
2
 or completely different effects. In view of 
our findings, future studies in this area should also 
consider metabolites which could be produced from 
Cryptococcus eicosanoids within the host.
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Figure 1. Evidenced and potential pathways of eicosanoid 
and PPAR-gamma interactions during Cryptococcus infection of 
macrophages.
Note. During infection, Cryptococcus resides within the phagosome. 
Prostaglandin E
2
 or 15-keto-PGE
2
 is produced by the fungus. Generation of 
15-keto-PGE
2
 is either by Cryptococcus or the host—or perhaps both. 15-
Keto PGE
2
 is a partial agonist to PPAR-gamma. PPAR-gamma is a cytosolic 
eicosanoid receptor; on ligand binding and activation, PPAR-gamma 
translocates to the nucleus where it binds to and activates genes with a 
PPRE target motif. In addition, prostaglandin E
2
 may bind its extracellular 
receptors EP2/4 on macrophages or other cells. PPAR = peroxisome 
proliferator–activated receptor; PPRE = peroxisome proliferator 
hormone response elements; PGDH = 15-hydroxy prostaglandin 
dehydrogenase.
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